Palvella Therapeutics, Inc. Investing Cash Flow
Palvella Therapeutics, Inc. (PVLA) reported Investing Cash Flow of -$62.47 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-04
- Palvella Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$7.03M.
- Palvella Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$55.44M.
- Palvella Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Palvella Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Palvella Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2023 was $12.00M.
- Palvella Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$21.24M.
- Palvella Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2021 was -$949.00K, a 102.42% decline from fiscal 2020.
- Palvella Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2020 was $39.21M, a 298.58% increase from fiscal 2019.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$7.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$62.47M 10-Q · filed 2026-08-04 | ||
| 2026-03-31 | -$55.44M 10-Q · filed 2026-05-07 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $0.00 10-Q · filed 2026-08-04 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | |||
| 2024-09-30 | $142.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $2.32M derived: sum of 2 quarters · filed 2024-11-13 | $11.32M 10-Q · filed 2024-11-13 | $14.77M derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | $2.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $11.18M 10-Q · filed 2024-08-14 | $14.63M derived: sum of 3 quarters · filed 2024-08-14 | $12.64M derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-03-31 | $9.00M 10-Q · filed 2024-05-15 | $12.45M derived: sum of 2 quarters · filed 2024-05-15 | $10.46M derived: sum of 3 quarters · filed 2024-11-13 | $9.10M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-12-31 | $3.45M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $1.47M derived: sum of 2 quarters · filed 2024-11-13 | $99.00K derived: sum of 3 quarters · filed 2024-11-13 | $12.00M 10-K · filed 2024-03-29 |
| 2023-09-30 | -$1.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$3.35M derived: sum of 2 quarters · filed 2024-11-13 | $8.55M 10-Q · filed 2024-11-13 | $9.66M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$1.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $10.54M 10-Q · filed 2024-08-14 | $11.64M derived: sum of 3 quarters · filed 2024-08-14 | $17.11M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $11.90M 10-Q · filed 2024-05-15 | $13.01M derived: sum of 2 quarters · filed 2024-05-15 | $18.48M derived: sum of 3 quarters · filed 2024-05-15 | $7.62M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $1.11M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $6.58M derived: sum of 2 quarters · filed 2024-03-29 | -$4.29M derived: sum of 3 quarters · filed 2024-03-29 | -$21.24M 10-K · filed 2024-03-29 |
| 2022-09-30 | $5.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$5.39M derived: sum of 2 quarters · filed 2023-11-14 | -$22.34M 10-Q · filed 2023-11-14 | -$22.68M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$10.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$27.81M 10-Q · filed 2023-08-10 | -$28.16M derived: sum of 3 quarters · filed 2023-08-10 | -$28.50M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$16.95M 10-Q · filed 2023-05-11 | -$17.29M derived: sum of 2 quarters · filed 2023-05-11 | -$17.64M derived: sum of 3 quarters · filed 2023-05-11 | -$17.87M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$342.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$692.00K derived: sum of 2 quarters · filed 2023-03-31 | -$921.00K derived: sum of 3 quarters · filed 2023-03-31 | -$949.00K 10-K · filed 2023-03-31 |
| 2021-09-30 | -$350.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | -$579.00K derived: sum of 2 quarters · filed 2022-11-04 | -$607.00K 10-Q · filed 2022-11-04 | $14.24M derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | -$229.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$257.00K 10-Q · filed 2022-08-04 | $14.59M derived: sum of 3 quarters · filed 2022-08-04 | $32.95M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$28.00K 10-Q · filed 2022-05-11 | $14.82M derived: sum of 2 quarters · filed 2022-05-11 | $33.17M derived: sum of 3 quarters · filed 2022-05-11 | $38.77M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $14.85M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $33.20M derived: sum of 2 quarters · filed 2022-03-02 | $38.80M derived: sum of 3 quarters · filed 2022-03-02 | $39.21M 10-K · filed 2022-03-02 |
| 2020-09-30 | $18.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $23.95M derived: sum of 2 quarters · filed 2021-11-02 | $24.36M 10-Q · filed 2021-11-02 | $22.48M derived: sum of 4 quarters · filed 2021-11-02 |
| 2020-06-30 | $5.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $6.01M 10-Q · filed 2021-08-05 | $4.13M derived: sum of 3 quarters · filed 2021-08-05 | $8.25M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $414.00K 10-Q · filed 2021-05-17 | -$1.47M derived: sum of 2 quarters · filed 2021-05-17 | $2.66M derived: sum of 3 quarters · filed 2021-05-17 | $15.57M derived: sum of 4 quarters · filed 2021-05-17 |
| 2019-12-31 | -$1.88M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $2.24M derived: sum of 2 quarters · filed 2021-03-31 | $15.15M derived: sum of 3 quarters · filed 2021-03-31 | $9.84M 10-K · filed 2021-03-31 |
| 2019-09-30 | $4.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $17.04M derived: sum of 2 quarters · filed 2020-11-04 | $11.72M 10-Q · filed 2020-11-04 | $6.50M derived: sum of 4 quarters · filed 2020-11-04 |
| 2019-06-30 | $12.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $7.60M 10-Q · filed 2020-08-10 | $2.38M derived: sum of 3 quarters · filed 2020-08-10 | $55.78M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | -$5.32M 10-Q · filed 2020-05-11 | -$10.53M derived: sum of 2 quarters · filed 2020-05-11 | $42.87M derived: sum of 3 quarters · filed 2020-05-11 | -$5.90M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | -$5.22M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $48.18M derived: sum of 2 quarters · filed 2020-03-13 | -$582.00K derived: sum of 3 quarters · filed 2020-03-13 | -$8.88M 10-K · filed 2020-03-13 |
| 2018-09-30 | $53.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $4.63M derived: sum of 2 quarters · filed 2019-11-12 | -$3.66M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | -$48.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | -$57.06M 10-Q · filed 2019-08-09 | ||
| 2018-03-31 | -$8.29M 10-Q · filed 2019-05-10 | |||
| 2017-12-31 | -$45.88M 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |